Hershkoviz R, Greenspoon N, Mekori Y A, Hadari R, Alon R, Kapustina G, Lider O
Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Clin Exp Immunol. 1994 Feb;95(2):270-6. doi: 10.1111/j.1365-2249.1994.tb06522.x.
The Arg-Gly-Asp (RGD) cell adhesion motif has been demonstrated in various studies to play a pivotal role in leucocyte and platelet interactions with plasma and extracellular matrix (ECM) glycoproteins. The recognition of the RGD sequence is mediated by heterodimeric receptors designated integrins of the beta 1 subfamily, expressed on distinct cell types, including T lymphocytes. We have recently shown that flexible non-peptidic mimetics of RGD, in which the two ionic side groups were separated by a linear spacer of 11 atoms, bound specifically to the platelet integrin alpha 11b beta 3, and inhibited T cell-mediated immune responses. The present study was designed to (i) further characterize the structural requirements for RGD interactions with CD4+ T cells, and (ii) examine the mechanisms by which the RGD mimetics interfere with immune cell reactivity in vivo. We now report that freezing the conformational degrees of freedom in the spacer chain, which fixes the relative orientation of the guanidinium and carboxylate side groups in a favourable manner, results in a higher level of inhibition of T cell binding to immobilized fibronectin, an RGD-containing ECM glycoprotein. In vivo, treatment of mice with relatively low doses of the RGD mimetics, but not the RGD peptide, inhibited the elicitation of an adoptively transferred DTH reaction. This inhibition was achieved by direct impairment of the ability of antigen-primed lymph node cells to migrate and accumulate in inflammatory sites. Hence, we suggest that the design and production of non-peptidic mimetics of RGD offers a novel approach to study defined parameters related to the structure-function requirements of small adhesion epitopes. Furthermore, this approach could be used therapeutically to inhibit pathological processes which depend on RGD recognition.
精氨酸 - 甘氨酸 - 天冬氨酸(RGD)细胞黏附基序在多项研究中已被证明在白细胞和血小板与血浆及细胞外基质(ECM)糖蛋白的相互作用中起关键作用。RGD序列的识别由β1亚家族的异二聚体受体介导,这些受体被称为整合素,在包括T淋巴细胞在内的不同细胞类型上表达。我们最近发现,RGD的柔性非肽模拟物,其中两个离子侧基由11个原子的线性间隔基团隔开,能特异性结合血小板整合素αIIbβ3,并抑制T细胞介导的免疫反应。本研究旨在:(i)进一步表征RGD与CD4 + T细胞相互作用的结构要求,以及(ii)研究RGD模拟物在体内干扰免疫细胞反应性的机制。我们现在报告,冻结间隔链中的构象自由度,以有利的方式固定胍基和羧基侧基的相对取向,会导致对T细胞与固定化纤连蛋白(一种含RGD的ECM糖蛋白)结合的抑制水平更高。在体内,用相对低剂量的RGD模拟物而非RGD肽处理小鼠,可抑制过继转移的迟发型超敏反应(DTH)的激发。这种抑制是通过直接损害抗原致敏的淋巴结细胞在炎症部位迁移和聚集的能力实现的。因此,我们认为RGD非肽模拟物的设计和生产为研究与小黏附表位的结构 - 功能要求相关的特定参数提供了一种新方法。此外,这种方法可用于治疗性抑制依赖RGD识别的病理过程。